Evidence map›Paper›PMID 33048259›Full record

Trial reportClinical and experimental medicine2021

Pharmacodynamic biomarkers in metronomic chemotherapy: multiplex cytokine measurements in gastrointestinal cancer patients.

Paloma Valenzuela, Derrick Oaxaca, Teresa Di Desidero, Karla Parra, Georgialina Rodriguez, Marian Manciu, Giacomo Allegrini, Alfredo Falcone, Guido Bocci, Robert A Kirken and 1 more

Open access · greenAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and experimental medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Paloma Valenzuela *Border Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA.
Derrick Oaxaca *Border Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA.
Teresa Di Desidero *Division of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Karla ParraBorder Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA.
Georgialina RodriguezBorder Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA.
Marian ManciuDepartment of Physics, UTEP, El Paso, TX, USA.
Giacomo AllegriniDivision of Medical Oncology, Pontedera Hospital, Azienda USL of Pisa, Pontedera, Italy.
Alfredo FalconeOncology Unit 2, University Hospital of Pisa, Pisa, Italy.
Guido BocciDivision of Pharmacology, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
Robert A KirkenBorder Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA.
Giulio FranciaBorder Biomedical Research Center, University of Texas at El Paso (UTEP), El Paso, TX, USA. gfrancia@utep.edu.ORCID http://orcid.org/0000-0002-3752-3070
The University of Texas at El Paso · USUniversity of Pisa · ITAzienda Ospedaliera Universitaria Pisana · IT

Funding

STEERING COMMITTEEU54MD008149 · NIMHD · MOREHOUSE SCHOOL OF MEDICINE · PI OFILI, ELIZABETH O. · 2012 to 2018
$21.1M
RISE Scholars Program at UTEPR25GM069621 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI AGUILERA, RENATO J · 2004 to 2021
$11.2M
The role of breast cancer organ specific metastasis on the therapeutic impact of anti-cancer drugsSC1GM136630 · NIGMS · UNIVERSITY OF TEXAS EL PASO · PI FRANCIA, GIULIO · 2020 to 2023
$1.5M
Paclitaxel Directed Drug Screening: A New Strategy to Identify Anti-Cancer DrugsSC2CA211029 · NCI · UNIVERSITY OF TEXAS EL PASO · PI FRANCIA, GIULIO · 2016 to 2018
$453k
NCI NIH HHS SC2 CA211029NIGMS NIH HHS R25 GM069621NIGMS NIH HHS SC1 GM136630NIMHD NIH HHS U54 MD008149
6 · The paper itself

Abstract

Metronomic chemotherapy has shown promising antitumor activity in a number of malignancies. We previously reported a phase II clinical trial of metronomic UFT (a 5-fluorouracil prodrug; 100 mg/twice per day p.o.) and cyclophosphamide (CTX; 500 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCytokinesGastrointestinal NeoplasmsAdministration, MetronomicFollow-Up StudiesHumansPrognosisSurvival RateBiomarkers, TumorCytokinesBiomarkerGastrointestinal cancerImmune activationMetronomic chemotherapyProgression-free survival

Identifiers

PMID33048259
PMCPMC8006211
OpenAlexW3091966002

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.